Loading
Latest filing published 01 Oct 2026 for Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation), €16k. Read the official filing
No signal scores available.
Only one filing by Brook Riggins is known so far (1 October 2026): an open-market purchase, €16k, in Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation). That is too little to draw conclusions. This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration